|
Oman Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Oman Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Oman.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Omani pharmaceutical and healthcare industry.
Competitive intelligence, Omani pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Omani market.
The Oman Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Oman Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Omani pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Oman to test other views – a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Omani Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
- Exploit The Latest Competitive Omani Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Oman.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Oman Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Table: Oman Pharmaceuticals And Healthcare Industry SWOT |
| Oman Political SWOT Industry SWOT |
| Oman Economic SWOT |
| Oman Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Oman Market Summary |
| Regulatory Regime |
| Recent Regulatory Developments |
| Intellectual Property Regime |
| Table: Current IP Laws In Oman |
| Pricing And Reimbursement |
| Regional Price Harmonisation |
| Free Trade Agreements |
Chapter - Industry Developments |
| Epidemiology |
| Table: Oman Mortality Indicators, 2006 |
| Healthcare Sector |
| Table: Number Of Health Centres In Oman, By Region |
| Table: Number And Type Of Health Institutions In Oman |
| Private Healthcare Sector |
| Healthcare Funding |
| Healthcare Reforms |
| Table: Healthcare Reform Targets |
| Medical Tourism |
| International Collaboration |
| Pharmaceutical Sector |
| Domestic Industry |
| Foreign Industry |
| Recent Industry Developments |
| International Pharmaceutical Collaboration |
| Research And Biotechnology |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecasts |
| Table: Oman's Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Oman's Health Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Macroeconomic |
| Table: Oman – Economic Activity |
| Prescription Market Forecast |
| Table: Oman – Prescription Market Indicators, Historical Data and Forecasts (OMRmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Oman – Patented Drug Market Forecast, Historical Data and Forecasts |
| Generics Market Forecast |
| Table: Oman – Generics Market Indicators, Historical Data and Forecasts |
| OTC Market Forecast |
| Table: Oman – OTC Market Indicators, Historical Data and Forecasts (OMRmn unless otherwise stated) |
| Pharmaceutical Trade Forecast |
| Table: India's Export Of Pharmaceutical Products To GCC Countries (US$mn) |
| Table: Oman – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Oman – Other Healthcare Indicators, Historical Data and Forecasts |
| Key Risk To BMI's Forecasts |
Chapter - Competitive Landscape |
| Company Monitor |
| Multinationals |
| Novartis |
| Johnson & Johnson |
| Sanofi-Aventis |
| GlaxoSmithKline |
| Pfizer |
| Merck & Co |
| Bayer |
| Indigenous Manufacturers |
| Zynova/Oman Pharmaceutical Products (OPP) |
| National Pharmaceutical Industries (NPI) |
Chapter - BMI Forecast Modelling |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Oman Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In the BMI ‘s Business Environment Ranking matrix for Q209, Oman is once again ranked in 9th place (which is this time not shared with Morocco) out of the 17 regional markets surveyed in the Middle East and Africa (MEA) region. The country’s strengths as a destination for investment by foreign drugmakers include its wealthy and rapidly ageing population, preference for branded products, and an improved intellectual property (IT) environment. Additionally, the country has emerged as an important provider of medical tourism services, with Majan Development Company (MDC) scheduled to start the construction of US$1bn healthcare city near the country’s capital of Muscat. However, Oman’s strict price controls and small population continue to keep the overall pharmaceutical values at levels virtually negligible in global terms.
In fact, despite boasting one of the most efficient healthcare systems in the region, Oman’s pharmaceutical market was only worth US$117mn in 2008 at consumer prices. By 2013, we expect the market to grow at a compound annual growth rate (CAGR) of some 7.43%, which is higher than that of the larger market, such as Kuwait. However, at US$167mn in 2013, Oman’s pharmaceutical market will not command major attention of multinational companies, especially as the need for cost-containment in the largely publicly funded system increases in the coming years.
Still, US companies – especially those involved in research and production of novel long-term treatments - should benefit from an improvement in operating conditions, following the recently signed free trade agreement (FTA) between the two countries. In December 2008, an FTA was also signed between the Gulf Cooperation Council (GCC), of which Oman is a member, and Singapore, becoming the first-ever bloc-wide agreement. While the key desire of the two sides is to enhance air services, pharmaceuticals from Singapore are also likely to find a receptive audience across the GCC.
In the meantime, though Oman's financial sector is relatively insulated from global problems, the oil and gas sector's reliance on commercial finance will undermine some of the country's major economic projects. Economic activity will be hit by the tail-wind of the global financial crisis, but the healthcare sector financing seems assured following the news that - despite the sharp downturn in oil prices - Oman was planning to increase its budgetary expenditure in 2009 by almost 20%.. However, economic growth in 2009 will be significantly down on the 2008 figure (which we forecast to come in at 6.4%), and the loss of an annual US$7bn in oil export earnings over the previous year - as oil prices remain under sustained pressure in 2009 - will imperil new project activity, feeding through into a dampened domestic demand outlook.
|
Oman Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |